pTriEx-4 Neo DNA - Novagen

Description

• General description: The pTriEx<TMSYMBOL></TMSYMBOL>-4 Neo vector is designed to allow rapid characterization of target genes in E. coli, insect and vertebrate cells, and to allow rapid selection of stable transfected vertebrate cells expressing high levels of target gene. Expression in vertebrate cells is mediated by the CMV immediate early enhancer and promoter2. The drug selection marker is expressed under the control of the EMC virus Cap-Independent Translation Enhancer (CITE) sequence (or IRES), allowing rapid selection of transfected vertebrate cells using the drug G418 or neomycin sulfate. For expression in insect cells, pTriEx-4 Neo contains flanking baculovirus sequences to permit the generation of recombinant baculoviruses using the BacVector<TMSYMBOL></TMSYMBOL> System. In baculovirus-infected insect cells, expression is driven by the very late p10 promoter. Expression in E. coli is regulated by the tightly controlled T7lac promoter. Expression can be induced in hosts such as NovaBlue by infecting with λCE6, a phage that constitutively expresses T7 RNA polymerase from the λlpL and λpI promoters. Alternatively, pTriEx recombinant plasmids can be transferred into a (DE3)pLacI host that allows induction with IPTG. Native protein can be expressed by cloning into the Nco I site, or generated by cloning into the PshA I or Sma I sites and cleaving the fusion protein with enterokinase or thrombin, respectively.This product is sold for internal research use only. Any commercial use of this product, its components, and/or any derivatives thereof (including but not limited to proteins produced using the product or its components) (together and hereinafter the ′EMD Product′) requires signature of a written commercial use agreement with EMD Millipore Corporation or its successor-in-interest. Commercial use shall include but not be limited to: (1) use of the EMD Product to manufacture products for sale to third parties; (2) use of the EMD Product to provide services, information, or data to third parties in exchange for consideration; (3) use of the EMD Product for therapeutic, diagnostic or prophylactic purposes (including as part of a device, chip, assay or other product); or (4) resale of the EMD Product, whether or not such EMD Product is resold for research use. Nothing contained herein shall be deemed to represent or warrant that additional third party rights are not required for use of the EMD Product. Please direct any questions on these use restrictions to: licensing@milliporesigma.com.
• Warning: Toxicity: Standard Handling (A)
• Legal Information: NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany